InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod

/PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced an update in the timing of the dose selection in the ongoing phase III study CONCLUDE...

Related Keywords

Sweden ,Stockholm ,Russia ,Ukraine ,Swedish ,Johan Gil ,Jenny Sundqvist ,Prnewswire Index Pharmaceuticals Holding ,Kindex Pharmaceuticals ,Index Pharmaceuticals Holding ,Abuse Regulation ,Dex Pharmaceuticals ,Immunomodulatory Sequences ,Nasdaq First North Growth Market ,Addex Pharma ,Health Care Amp Hospitals ,Pharmaceuticals ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,